Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cell body

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,412 result(s) found for: Cell body. Displaying page 66 of 71.
    «« First « Previous 62  63  64  65  66  67  68  69  70  Next» Last»»
    EudraCT Number: 2018-001159-11 Sponsor Protocol Number: POL7080-010 Start Date*: 2019-02-08
    Sponsor Name:Polyphor Ltd.
    Full Title: A multicenter, open-label, sponsor-blinded, randomized, active-controlled, parallel group, pivotal study to evaluate the efficacy, safety, and tolerability of murepavadin given with ertapenem versu...
    Medical condition: Nosocomial pneumonia
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10052596 Nosocomial pneumonia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) FR (Prematurely Ended) LT (Prematurely Ended) HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-003570-77 Sponsor Protocol Number: SB010/04/2012 Start Date*: 2012-12-04
    Sponsor Name:sterna biologicals GmbH & Co. KG
    Full Title: Clinical study to investigate safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of multiple doses of the human GATA-3-specific DNAzyme solution SB010 in patients with mild aller...
    Medical condition: The trial will be conducted in 38 male patients with mild allergic asthma and documented or known biphasic reaction to allergen challenge (AC).
    Disease: Version SOC Term Classification Code Term Level
    15.0 10038738 - Respiratory, thoracic and mediastinal disorders 10001705 Allergic asthma LLT
    Population Age: Adults Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-001048-40 Sponsor Protocol Number: B1371013 Start Date*: 2015-02-10
    Sponsor Name:Pfizer Inc. 235 East 42nd Street, New York, 10017
    Full Title: A phase 2, double-blind, randomized safety and efficacy study of Glasdegib (PF-04449913) versus placebo in patients with Myelofibrosis previously treated with ruxolitinib.
    Medical condition: Myelofibrosis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028537 Myelofibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) AT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2014-000619-14 Sponsor Protocol Number: GBG84 Start Date*: 2014-11-04
    Sponsor Name:German Breast Group
    Full Title: A randomized phase III trial comparing two dose-dense, dose-intensified approaches (ETC and PM(Cb)) for neoadjuvant treatment of patients with high-risk early breast cancer (GeparOcto)
    Medical condition: Patients with primary breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-001930-93 Sponsor Protocol Number: GC-627-04 Start Date*: 2017-01-13
    Sponsor Name:Generon (Shanghai) Corporation Ltd.
    Full Title: A Phase III, Randomized, Multi-Centre, Double-Blind, Placebo Controlled Clinical Trial of F-627 in Women with Breast Cancer Receiving Myelotoxic Chemotherapy
    Medical condition: Women, between 18 and 75 years of age that have been diagnosed with Stage II-IV breast cancer in the adjuvant or metastatic setting and are scheduled to undergo chemotherapy. This is a profilaxis ...
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    19.0 10005329 - Blood and lymphatic system disorders 10016288 Febrile neutropenia PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2014-000828-24 Sponsor Protocol Number: ANRS163ETRAL Start Date*: 2015-05-31
    Sponsor Name:Inserm-ANRS
    Full Title: A non-comparative phase II trial evaluating the capacity of the dual combination raltegravir/etravirine to maintain virological success in HIV-1 infected patients of at least 45 years of age with a...
    Medical condition: HIV infection
    Disease: Version SOC Term Classification Code Term Level
    18.0 10021881 - Infections and infestations 10020161 HIV infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2013-002895-42 Sponsor Protocol Number: GITS2013_4.0 Start Date*: 2013-10-10
    Sponsor Name:Region Västerbotten
    Full Title: Glaucoma Intensity Treatment Study – Intensive non-invasive glaucoma treatment vs conventional stepwise treatment – a prospective, randomized phase IV study of disease progression in glaucoma (GITS...
    Medical condition: Glaucoma, open-angle and PEX glaucoma.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10030856 Open-angle glaucoma LLT
    20.0 100000004853 10037118 Pseudoexfoliation glaucoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-000561-33 Sponsor Protocol Number: TOL-2 Start Date*: 2022-03-08
    Sponsor Name:TolerogenixX GmbH
    Full Title: An open, randomized-controlled, multi-center phase-II clinical trial of individualized immunosuppression with intravenously administered donor modified immune cells (MIC) compared to standard-of-ca...
    Medical condition: Living donor kidney transplantation
    Disease: Version SOC Term Classification Code Term Level
    20.0 10042613 - Surgical and medical procedures 10023438 Kidney transplant LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-003461-34 Sponsor Protocol Number: UR1840 Start Date*: 2019-07-09
    Sponsor Name:Department of Oncology, Herlev & Gentofte Hospital
    Full Title: Randomised phase 2 trial of stereotactic body radiation therapy, SBRT, in combination with checkpoint inhibitors in metastatic castration-resistant prostate cancer
    Medical condition: metastatic castration-resistant prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036920 Prostate cancer stage IV PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10076506 Castration-resistant prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-001244-95 Sponsor Protocol Number: MK-3475-C11 Start Date*: 2021-07-30
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: Phase 2 Study of Pembrolizumab and Chemotherapy in Patients With Newly Diagnosed Classical Hodgkin Lymphoma (KEYNOTE-C11)
    Medical condition: Classical Hodgkin Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10080208 Classical Hodgkin lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-005770-26 Sponsor Protocol Number: KRONF2 Start Date*: 2023-10-20
    Sponsor Name:Medical University of Warsaw
    Full Title: Phase 2a non-commercial and non-randomized intervention study evaluating the efficacy of crizotinib in the treatment of children with severe type 2 neurofibromatosis, in particular those excluded f...
    Medical condition: Neurofibromatosis type 2 is a genetically determined primary malignancy resulting from a mutation that disables the function of the cell division control gene and leads to neoplasia such as benign ...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000523 Acoustic neuroma PT
    27.0 10010331 - Congenital, familial and genetic disorders 10029271 Neurofibromatosis, type 2 (acoustic neurofibromatosis) LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-001823-38 Sponsor Protocol Number: AB65/18 Start Date*: 2018-11-26
    Sponsor Name:Technische Universität München, Fakultät für Medizin vertreten durch den Dekan
    Full Title: A prospective, single arm, multicenter, phase II-trial to assess safety and efficacy of preoperative RAdiation therapy before radical CystEctomy combined with ImmunoTherapy in locally advanced urot...
    Medical condition: Locally advanced urothelial bladder cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005003 Bladder cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-002044-28 Sponsor Protocol Number: HGT-MLD-070 Start Date*: 2012-06-14
    Sponsor Name:Shire Human Genetics Therapies Inc
    Full Title: A Phase I/II, Multicenter, Open-label, Dose Escalation Study of HGT-1110 Administered Intrathecally in Children with Metachromatic Leukodystrophy
    Medical condition: Treatment of Metachromatic Leukodystrophy
    Disease: Version SOC Term Classification Code Term Level
    19.0 10010331 - Congenital, familial and genetic disorders 10067609 Metachromatic leukodystrophy PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2009-011055-43 Sponsor Protocol Number: GENA-08 Start Date*: 2009-10-22
    Sponsor Name:Octapharma AG
    Full Title: Clinical Study to Investigate the Efficacy, Safety, and Immunogenicity of human-cl rhFVIII in Previously Treated Patients With Severe Haemophilia A
    Medical condition: Severe haemophilia A (FVIII:C <=1%)
    Disease: Version SOC Term Classification Code Term Level
    13.1 10010331 - Congenital, familial and genetic disorders 10018937 Haemophilia A LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male
    Trial protocol: DE (Completed) AT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-003664-32 Sponsor Protocol Number: 201301 Start Date*: 2014-03-26
    Sponsor Name:Medical Center Alkmaar
    Full Title: ‘Effect of omega-3 fatty acids on the perioperative immune response and erythrocyte function’
    Medical condition: Patients undergoing colon surgery for malignancy.
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10009951 Colon cancer NOS LLT
    17.0 100000004864 10009950 Colon cancer Duke's D LLT
    17.0 100000004864 10009946 Colon cancer Duke's A LLT
    17.0 100000004864 10009947 Colon cancer Duke's B1 LLT
    17.0 100000004864 10009948 Colon cancer Duke's B2 LLT
    17.0 100000004864 10009949 Colon cancer Duke's C LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-001472-22 Sponsor Protocol Number: IMUNOR-201501 Start Date*: 2017-03-14
    Sponsor Name:ImunomedicA, a.s.
    Full Title: A Prospective, Randomized, Double-Blind, Placebo-controlled, Multicenter, Phase III Study Assessing Efficacy and Safety of the IMUNOR® Therapy Versus Placebo in Patients with Recurrent Vulvovaginit...
    Medical condition: Recurrent vulvovaginitis episodes
    Disease: Version SOC Term Classification Code Term Level
    19.0 10021881 - Infections and infestations 10047794 Vulvovaginitis PT
    Population Age: Adults Gender: Female
    Trial protocol: SK (Completed) CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-005674-11 Sponsor Protocol Number: ADVL1412 Start Date*: 2015-04-08
    Sponsor Name:National Cancer Institute
    Full Title: A PHASE 1/2 STUDY OF NIVOLUMAB (IND# 124729) IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH RECURRENT OR REFRACTORY SOLID TUMORS AS A SINGLE AGENT AND IN COMBINATION WITH IPILIMUMAB
    Medical condition: •Childhood Solid Neoplasm •Recurrent Childhood Rhabdomyosarcoma •Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor •Recurrent Neuroblastoma •Recurrent Osteosarcoma •Recurrent ...
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10031296 Osteosarcoma recurrent PT
    17.1 10005329 - Blood and lymphatic system disorders 10025319 Lymphomas Hodgkin's disease HLGT
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029600 Non-Hodgkin's lymphoma recurrent PT
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066595 Neuroblastoma recurrent PT
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015564 Ewing's sarcoma recurrent PT
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10039027 Rhabdomyosarcoma recurrent PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2021-002073-26 Sponsor Protocol Number: 1125-ECIR Start Date*: Information not available in EudraCT
    Sponsor Name:Medical Center - University of Freiburg
    Full Title: Phase 1/2 Trial to determine the safety and efficacy of Extracorporeal photopheresis as treatment for steroid-refractory immune related adverse events after immune checkpoint inhibitor therapy
    Medical condition: Immune related adverse events induced by treatment with immune checkpoint inhibitors (monoclocanl antibodies against PD-1, PD-L1 or CTLA-4)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10022117 - Injury, poisoning and procedural complications 10043408 Therapeutic agent toxicity LLT
    26.1 10018065 - General disorders and administration site conditions 10067033 Drug side effect LLT
    24.0 10018065 - General disorders and administration site conditions 10061623 Adverse drug reaction PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-001238-16 Sponsor Protocol Number: CNTO1959PSO3012 Start Date*: 2019-01-03
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 3b, Randomized, Double-blind, Active-controlled, Multicenter Study to Evaluate Further Therapeutic Strategies with Guselkumab in Patients with Moderate-to-Severe Plaque-Type Psoriasis
    Medical condition: Moderate to Severe Plaque Type Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-003418-18 Sponsor Protocol Number: SMR2268/TheMIBSStudy Start Date*: 2012-01-09
    Sponsor Name:Sahlgrenska University Hospital
    Full Title: A Randomised, Double Blind, Placebo Controlled, Multi-centre, Parallel Group, Interventional Study of Mesalazine (Asacol®) Treatment in IBS and the Evaluation of Rectal Inflammatory Status using th...
    Medical condition: Irritable Bowel Syndrome
    Disease: Version SOC Term Classification Code Term Level
    14.1 10017947 - Gastrointestinal disorders 10023003 Irritable bowel syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) NO (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 62  63  64  65  66  67  68  69  70  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Jun 12 14:59:50 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA